C. Twelves

Andreas Schätzlein, Chris Twelves, Carol McCormick, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

U. Banerji, J. Spicer, D. Josephs, 2014, Clinical Cancer Research.

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors   

G. Kroemer, J. Soria, J. Armand, 2011, Cell cycle.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

Lucy F. Stead, G. Nuovo, M. Coffey, 2018, Science Translational Medicine.

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.

Rob Jones, Chris Twelves, J. Baselga, 2008, European journal of cancer.

Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.

J. Meyerhardt, D. Sargent, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine as adjuvant treatment for stage III colon cancer.

Markus Abt, Joseph McKendrick, Marek Pawlicki, 2005, The New England journal of medicine.

Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis.

J. Beattie, V. Speirs, C. Twelves, 2013, Biochimica et biophysica acta.

The Clinical Development of Lurtotecan

K. Flaherty, P. O'dwyer, C. Twelves, 2005 .

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.

L. Paz-Ares, P. O'dwyer, S. Kaye, 1998, British Journal of Cancer.

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial

D. Haller, M. Saif, H. Schmoll, 2014, British Journal of Cancer.

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

C. Twelves, I. Macpherson, T. Evans, 2012, BMC Cancer.

Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors

C. Twelves, J. Cassidy, P. Schöffski, 2005, Clinical Cancer Research.

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.

R. Prescott, J. Bartlett, D. Cameron, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework

C. Twelves, K. Saini, 2021, British Journal of Cancer.

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

C. Hiley, A. Ryan, C. Faivre-Finn, 2020, Clinical and translational radiation oncology.

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.

N. Ibrahim, H. Rugo, C. Anders, 2019, Future oncology.

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

R. Plummer, C. Twelves, T. Evans, 2019, British Journal of Cancer.

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

H. Earl, D. Rea, S. M. Crawford, 2006, The New England journal of medicine.

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.

C. Twelves, J. Menis, 2011, Breast cancer.

Long-term clinical effect and safety of sebelipase alfa in adults with lysosomal acid lipase deficiency

C. Twelves, S. Eckert, E. Schneider, 2014 .

The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.

D. Fabbro, A. Harris, F. Caponigro, 1999, Cancer research.

Capecitabine in colorectal cancer

C. Twelves, M. Braun, 2009 .

Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro

J. Beattie, V. Speirs, C. Twelves, 2016, Oncotarget.

Defining the optimal schedule of drug administration: art or science?

C. Twelves, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?

C. Twelves, J. Cassidy, CJ Twelves, 2002, British Journal of Cancer.

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.

H. Burger, J. Verweij, E. Van Cutsem, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

B. Reigner, J. Verweij, J. Schellens, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies

U. Gatzemeier, S. Kaye, C. Twelves, 2003, Cancer Chemotherapy and Pharmacology.

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

C. Caldas, E. Provenzano, H. Earl, 2010, The Lancet. Oncology.

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

I. Ellis, M. Dowsett, P. Ellis, 2009, The Lancet.

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

C. Twelves, A. Awada, V. Diéras, 2018, Cancer treatment reviews.

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma

J. Panse, M. Sabel, R. Fietkau, 2021, British Journal of Cancer.

Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

N. Brünner, E. Balslev, J. Bartlett, 2013, Breast Cancer Research.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

C. Sotiriou, C. Desmedt, D. Larsimont, 2011, The Lancet. Oncology.

Protein kinase C: a target for anticancer drugs?

H. Mackay, C. Twelves, 2003, Endocrine-related cancer.

A phase I dose-escalation study of zd0473 combined with paclitaxel in refractory solid malignancies

U. Gatzemeier, C. Twelves, G. Pentheroudakis, 2001 .

Clinical Grade OK432-activated Dendritic Cells: In Vitro Characterization and Tracking During Intralymphatic Delivery

A. Dietz, A. Melcher, C. Twelves, 2009, Journal of immunotherapy.

Influence of dexamethasone dose on the control of chemotherapy-induced nausea and vomiting.

C. Twelves, R. Rubens, R. Coleman, 1991, European journal of cancer.

A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

R. Eastell, C. Twelves, I. Macpherson, 2022, Journal of bone oncology.

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

J. Bartlett, C. Poole, L. Hopcroft, 2023, Breast Cancer Research and Treatment.

A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer.

R. Glasspool, I. McNeish, C. Twelves, 2015 .

Toxicity of intra-arterial doxorubicin in locally advanced breast cancer

C. Twelves, R. Rubens, J. Reidy, 2004, Cancer Chemotherapy and Pharmacology.

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

M. Piccart, A. Bottomley, T. Čufer, 2004, European journal of cancer.

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

O. Schoor, S. Halford, C. Twelves, 2016, Clinical Cancer Research.

Br. J. Cancer '."

N. Dobbs, C. Twelves, R. Rubens, 2022 .

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

E. Perez, H. Rugo, J. Ahn, 2017, Breast Cancer Research and Treatment.

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

A. Harris, T. Ganesan, J. Braybrooke, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd P harmacokinetic S tudy o f P KC412, a n Inhibitor o f P rotein K inase C

A. Harris, F. Caponigro, F. Balkwill, 2001 .

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

P. Beale, N. Bleehen, P. Vasey, 1999, British Journal of Cancer.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

W. Scheithauer, J. Zaluski, H. Burris, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer

Lincoln D. Stein, P. Boutros, J. Bartlett, 2016, Breast Cancer Research.

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

R. Butler, C. Twelves, R. Venkitaraman, 2020, The Lancet. Oncology.

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.

A. Schätzlein, J. Sludden, A. Boddy, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer

S. Kaye, D. Bisset, P. Vasey, 2002, British Journal of Cancer.

Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

R. Butler, C. Twelves, R. Venkitaraman, 2019, Journal of Clinical Oncology.

Chemotherapy of advanced breast cancer: outcome and prognostic factors.

R. K. Knight, W. Gregory, C. Twelves, 1993, British Journal of Cancer.

A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials

P. Boutros, J. Bartlett, Fouad Yousif, 2015, Oncotarget.

Cost-Effective Strategies in the Management of Advanced Colorectal Cancer

C. Twelves, L. Scott, 2003 .

Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.

J. Ledermann, D. Cameron, J. Crown, 2004, Journal of the National Cancer Institute.

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

M. Piccart, L. Duchateau, C. Lohrisch, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer and liver metastases--incidence, diagnosis and outcome.

C. Twelves, M. Richards, S. O’Reilly, 1992, Journal of the Royal Society of Medicine.

Sunbed use in children aged 11-17 in England: face to face quota sampling surveys in the National Prevalence Study and Six Cities Study

C. Twelves, S. Hiom, C. Thomson, 2010, BMJ : British Medical Journal.

Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance.

M. Clench, P. Loadman, C. Twelves, 2019, Critical reviews in oncology/hematology.

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.

C. Twelves, R. Rubens, R. Coleman, 1989, British Journal of Cancer.

'Tablet burden' in patients with metastatic breast cancer.

C. Twelves, M. Milić, A. Anthoney, 2016, European journal of cancer.

Chemotherapy in patients with heavily pretreated metastatic breast cancer: overview

C. Twelves, M. Fornier, 2012 .

Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer.

W. Gradishar, H. Rugo, C. Twelves, 2014, Clinical advances in hematology & oncology : H&O.

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.

Chris Twelves, A. Ravaud, J. Wanders, 2005, European journal of cancer.

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

P. Jones, M. Albertella, P. Loadman, 2008, Clinical Cancer Research.

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

E. Perez, M. Olivo, C. Twelves, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry

N. Dobbs, C. Twelves, R. Rubens, 2004, Cancer Chemotherapy and Pharmacology.

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Daniel J Sargent, Greg Yothers, Lindsay A Renfro, 2014, Journal of the National Cancer Institute.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

R. Labianca, D. Kerr, D. Sargent, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer.

H. Mackay, D. Bissett, P. Vasey, 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).

Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling.

N. Dobbs, C. Twelves, A. Thomson, 2004, British journal of clinical pharmacology.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

J. Wanders, J. Beijnen, J. Smyth, 2003, European journal of cancer.

Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

E. Perez, H. Rugo, S. Im, 2018, Clinical Cancer Research.

Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients withAdvancedBreastCancerafterTreatmentwith

E. Perez, H. Rugo, S. Im, 2018 .

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT)

I. Ellis, M. Dowsett, P. Ellis, 2009 .

Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.

P. Kabos, C. Twelves, N. Turner, 2022, Journal of Clinical Oncology.

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

A. Cohen, U. Banerji, P. Kabos, 2021 .

A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.

U. Banerji, C. Twelves, R. Baird, 2020 .

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

C. Weitzel, C. Twelves, J. Cassidy, 2001, European journal of cancer.

Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

D. Bissett, C. Twelves, J. Cassidy, 2004, British Journal of Cancer.

A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.

H. Mackay, R. Glasspool, D. Cunningham, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy

Geoff Hall, Jose Leal, Karl Baker, 2017, Int. J. Medical Informatics.

Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.

D. Sargent, B. Bot, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

J. Beijnen, J. Double, P. Loadman, 2006, The Journal of urology.

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

D. Jodrell, C. Twelves, J. Cassidy, 1998, British Journal of Cancer.

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

M. Ranson, I. Melezínek, G. Klingelschmitt, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

S. Loibl, G. Curigliano, C. Twelves, 2020, British Journal of Cancer.

Legislation is needed to stop children using sunbeds

C. Twelves, C. Thomson, 2009, BMJ : British Medical Journal.

Sequential chemotherapy in good-prognosis patients with small-cell lung cancer

R. Souhami, D. Geddes, C. Twelves, 2004, Cancer Chemotherapy and Pharmacology.

Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma

D. Thomas, R. Souhami, D. Miles, 2004, Cancer Chemotherapy and Pharmacology.

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

M. O’connell, D. Haller, G. Yothers, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis

C. Twelves, J. Cortés, 2019, The breast journal.

A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy.

L. Frenz, I. Judson, C. Twelves, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients

B. Reigner, K. O'Byrne, D. Cameron, 1999, Cancer Chemotherapy and Pharmacology.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

D. Lacombe, J. Verweij, J. Schellens, 2012, British Journal of Cancer.

A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid

C. Twelves, J. Cassidy, M. Devlin, 2004, Cancer Chemotherapy and Pharmacology.

Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.

E. Perez, H. Rugo, S. Im, 2015 .

Abstract P1-12-08: Quality of Life in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes who Received Eribulin Mesylate or Capecitabine in a Phase III, Open-label, Randomized Study

J. Wanders, M. Olivo, C. Twelves, 2012 .

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

J. Baselga, G. von Minckwitz, D. Fumagalli, 2019, Cancer Chemotherapy and Pharmacology.

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis

J. O’Shaughnessy, C. Twelves, L. Goldstein, 2020, Scientific Reports.

“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

E. Perez, J. O’Shaughnessy, M. Olivo, 2015, Breast Cancer Research.

A mathematical model of doxorubicin penetration through multicellular layers.

S W Smye, P M Loadman, B. Sleeman, 2009, Journal of theoretical biology.

A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.

E. Perez, J. Wanders, M. Olivo, 2013 .

Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.

E. Perez, J. Wanders, M. Olivo, 2013 .

Capecitabine monotherapy in metastatic colorectal cancer.

J. Nguyen-Van-Tam, D. Hargreaves, C. Twelves, 2001, The Lancet. Oncology.

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

R. Plummer, C. Twelves, T. Evans, 2019, British Journal of Cancer.

E. Perez, H. Rugo, J. Ahn, 2017, European journal of cancer.

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

E. Perez, H. Rugo, S. Im, 2016, SpringerPlus.

FOLINIC ACID RESCUE AND METHOTREXATE TOXICITY

C. Twelves, 1986, The Lancet.

Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests

N. Dobbs, C. Twelves, R. Rubens, 1998, Cancer Chemotherapy and Pharmacology.

Vision of the future: capecitabine.

C. Twelves, C Twelves, 2001, The oncologist.

Loading doses for costly cancer biologicals: a cause for concern or tilting at windmills?

C. Twelves, I. Hennig, 2008, European journal of cancer.

Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?

N. Dobbs, C. Twelves, 1998, British Journal of Cancer.

Measurement of epidoxorubicin and its metabolites by high-performance liquid chromatography using an advanced automated sample processor.

N. Dobbs, C. Twelves, 1991, Journal of chromatography.

Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification.

Philip Smith, C. Twelves, R. Rubens, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral Capeci tabine Compared With Intravenous Fluorourac i l Plus Leucovor in in Pat ients With Metastat ic Colorecta l Cancer : Resul ts of a Large Phase III Study

P. Rougier, W. Schmiegel, C. Weitzel, 2001 .

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.

A. Melcher, C. Twelves, F. Collinson, 2018 .

Capecitabine plus docetaxel combination therapy

J. Hornberger, D. Miles, J. O’Shaughnessy, 2005, Cancer.

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.

N. Ibrahim, H. Rugo, C. Anders, 2022, JAMA oncology.

1057PDFINAL RESULTS FROM A CANCER RESEARCH UK FIRST IN MAN PHASE I TRIAL OF IMA950 (A NOVEL MULTI PEPTIDE VACCINE) PLUS GM-CSF IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA.

O. Schoor, S. Halford, C. Twelves, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

N. Strelkowa, J. Yang, Chih-Hung Hsu, 2020, British Journal of Cancer.

Phase I and pharmacokinetic study of ecteinascldin-743 (ET-743) given as a one hour infusion every 21 days

J. Beijnen, J. Smyth, C. Twelves, 1997 .

Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub‐types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial

Carlos Caldas, Elena Provenzano, C. Caldas, 2013, International journal of cancer.

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer

R. Plummer, M. Ranson, C. Twelves, 2014, Anti-cancer drugs.

A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM).

C. Twelves, S. Short, S. Wright, 2017 .

FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.

M. Knowles, P. Loadman, C. Twelves, 2016 .

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study

C. Caldas, J. Abraham, H. Earl, 2016, PloS one.

Patient acceptability and practical implications of pharmacokinetic studies in patients with advanced cancer.

N. Dobbs, C. Twelves, A. Ramirez, 1993, European journal of cancer.

W. Scheithauer, C. Twelves, J. Cassidy, 2012 .

“New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

E. Perez, J. O’Shaughnessy, M. Olivo, 2015, Breast Cancer Research.

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

R. Butler, G. Schiavon, C. Twelves, 2022, Journal of Clinical Oncology.

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

C. Twelves, A. Awada, V. Diéras, 2018, Cancer treatment reviews.

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.

C. Twelves, A. Awada, M. Jové, 2016, Critical reviews in oncology/hematology.

Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer

J. Douillard, C. Twelves, J. Cassidy, 2005 .

Immune Recruitment and Therapeutic Synergy: Keys to Optimizing Oncolytic Viral Therapy?

R. Vile, C. Twelves, P. Selby, 2011, Clinical Cancer Research.

The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results

R. Plummer, M. Ranson, C. Twelves, 2005 .

AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)

L. Duchateau, T. Čufer, C. Twelves, 2000 .